Insight Eyecare

InSite Vision, now a subsidiary of Sun Pharmaceutical Industries, is a specialty pharmaceutical company focused on the development and commercialization of ophthalmic therapies. The company is distinguished by its proprietary DuraSite and DuraSite 2 drug delivery platforms, which are designed to enhance the topical delivery of drugs to the eye by extending their residence time on the ocular surface. InSite Vision's commercial portfolio includes AzaSite (azithromycin) for bacterial conjunctivitis and BromSite (bromfenac) for the treatment of inflammation and pain following cataract surgery. Additionally, the company developed Besivance (besifloxacin), which is marketed by Bausch + Lomb under a global licensing agreement. The company's pipeline has historically included combination therapies and enhanced formulations of anti-infective and anti-inflammatory agents targeting conditions such as blepharitis and conjunctivitis.